Nuacht

Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi
Nuvation Bio (NUVB) wins U.S. FDA approval for its oral antitumor agent Ibtrozi as a treatment for certain patients with ...
Business Wire3 lá
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung …
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer ...
US FDA approves Nuvation Bio's rare lung cancer drug
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...
The Pharma Letter2 lá
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC
The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...
Investing1 lá
Nuvation Bio price target maintained at $6 by Citizens JMP
Citizens JMP analyst reiterated a Market Outperform rating and $6.00 price target on Nuvation Bio Inc (NYSE: NUVB) stock Friday, despite the stock’s recent 27% decline over the past week.
US FDA approves Nuvation Bio's lung cancer therapy
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...
Contract Pharma2 lá
U.S. FDA Approves Nuvation Bio’s Ibtrozi
Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...
Investing1 lá
Nuvation Bio stock holds steady as FDA approves lung cancer drug
The U.S. Food and Drug Administration granted full approval to Nuvation Bio Inc’s (NYSE:NUVB) lung cancer drug IBTROZI this week. The announcement comes as the company’s stock trades at $1.81 ...